JP2022536419A5 - - Google Patents
Info
- Publication number
- JP2022536419A5 JP2022536419A5 JP2021573595A JP2021573595A JP2022536419A5 JP 2022536419 A5 JP2022536419 A5 JP 2022536419A5 JP 2021573595 A JP2021573595 A JP 2021573595A JP 2021573595 A JP2021573595 A JP 2021573595A JP 2022536419 A5 JP2022536419 A5 JP 2022536419A5
- Authority
- JP
- Japan
- Prior art keywords
- biphenyl
- carboxylic acid
- ylmethoxy
- pyridine
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962860677P | 2019-06-12 | 2019-06-12 | |
| US62/860,677 | 2019-06-12 | ||
| PCT/US2020/037549 WO2020252353A1 (en) | 2019-06-12 | 2020-06-12 | Amino acid transport inhibitors and the uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022536419A JP2022536419A (ja) | 2022-08-16 |
| JP2022536419A5 true JP2022536419A5 (cg-RX-API-DMAC7.html) | 2023-06-21 |
Family
ID=71950790
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021573595A Pending JP2022536419A (ja) | 2019-06-12 | 2020-06-12 | アミノ酸輸送阻害剤及びその使用 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20220304984A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3983084A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2022536419A (cg-RX-API-DMAC7.html) |
| CN (1) | CN114222729A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2020291464A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3141405A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2020252353A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019217307A1 (en) | 2018-05-07 | 2019-11-14 | Mirati Therapeutics, Inc. | Kras g12c inhibitors |
| SMT202500028T1 (it) | 2018-09-10 | 2025-03-12 | Mirati Therapeutics Inc | Terapie combinate |
| CA3112043A1 (en) | 2018-09-10 | 2020-03-19 | Mirati Therapeutics, Inc. | Combination therapies |
| US12208099B2 (en) | 2018-09-10 | 2025-01-28 | Mirati Therapeutics, Inc. | Combination therapies |
| AU2019338207B2 (en) | 2018-09-10 | 2025-01-02 | Mirati Therapeutics, Inc. | Combination therapies |
| US12377101B2 (en) | 2018-12-05 | 2025-08-05 | Mirati Therapeutics, Inc. | Combination therapies |
| WO2020146613A1 (en) | 2019-01-10 | 2020-07-16 | Mirati Therapeutics, Inc. | Kras g12c inhibitors |
| CN114615981B (zh) | 2019-08-29 | 2024-04-12 | 米拉蒂治疗股份有限公司 | Kras g12d抑制剂 |
| CN114761012B (zh) | 2019-09-24 | 2025-03-21 | 米拉蒂治疗股份有限公司 | 组合疗法 |
| PH12022551513A1 (en) | 2019-12-20 | 2023-04-24 | Mirati Therapeutics Inc | Sos1 inhibitors |
| US12655160B2 (en) | 2020-08-04 | 2026-06-16 | Mirati Therapeutics, Inc. | KRAS G12D inhibitors |
| EP4210833A4 (en) | 2020-09-11 | 2024-09-11 | Mirati Therapeutics, Inc. | CRYSTALLINE FORMS OF A KRAS G12C INHIBITOR |
| EP4216951B1 (en) | 2020-09-22 | 2026-04-01 | Mirati Therapeutics, Inc. | Kras g12d inhibitors |
| EP4262807A4 (en) | 2020-12-15 | 2025-04-23 | Mirati Therapeutics, Inc. | Azachinazoline pan-KRAS inhibitors |
| WO2022133038A1 (en) | 2020-12-16 | 2022-06-23 | Mirati Therapeutics, Inc. | Tetrahydropyridopyrimidine pan-kras inhibitors |
| US20240174658A1 (en) * | 2021-03-01 | 2024-05-30 | Vanderbilt University | Heteroaromatic Inhibitors of Cancer Metabolism |
| WO2024010732A1 (en) * | 2022-07-05 | 2024-01-11 | Board Of Regents, The University Of Texas System | Small molecule inhibitors of glutamine transporter asct2 and methods of use thereof |
| CN115894459B (zh) * | 2023-01-04 | 2025-05-27 | 中国药科大学 | 一种2-苯并呋喃羧酸衍生物及其制备方法与用途 |
| JP2026508178A (ja) * | 2023-02-14 | 2026-03-10 | シェンチェン ジョンジー バイオロジカル テクノロジー カンパニー, リミテッド | Nlrp3を阻害する化合物及びその製造方法と応用 |
Family Cites Families (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR8108820A (pt) | 1980-09-24 | 1982-08-24 | Cetus Corp | Processo e sonda de diagnostico |
| EP0084796B1 (en) | 1982-01-22 | 1990-05-02 | Cetus Corporation | Hla typing method and cdna probes used therein |
| US4582788A (en) | 1982-01-22 | 1986-04-15 | Cetus Corporation | HLA typing method and cDNA probes used therein |
| US4683194A (en) | 1984-05-29 | 1987-07-28 | Cetus Corporation | Method for detection of polymorphic restriction sites and nucleic acid sequences |
| US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| CA1284931C (en) | 1986-03-13 | 1991-06-18 | Henry A. Erlich | Process for detecting specific nucleotide variations and genetic polymorphisms present in nucleic acids |
| CA1338457C (en) | 1986-08-22 | 1996-07-16 | Henry A. Erlich | Purified thermostable enzyme |
| US5093330A (en) | 1987-06-15 | 1992-03-03 | Ciba-Geigy Corporation | Staurosporine derivatives substituted at methylamino nitrogen |
| US6605712B1 (en) | 1990-12-20 | 2003-08-12 | Arch Development Corporation | Gene transcription and ionizing radiation: methods and compositions |
| EP0970128A1 (en) | 1997-03-21 | 2000-01-12 | Brigham And Women's Hospital | Immunotherapeutic ctla-4 binding peptides |
| ES2539411T3 (es) | 1999-08-23 | 2015-06-30 | Dana-Farber Cancer Institute, Inc. | PD-1, receptor para la B7-4 y su utilización |
| NZ517202A (en) | 1999-08-24 | 2004-05-28 | Medarex Inc | Human CTLA-4 antibodies and their uses |
| JP4637481B2 (ja) * | 2001-10-19 | 2011-02-23 | オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド | Cds1/chk2阻害剤および癌治療における化学療法または放射線療法の補助剤としての2−フェニルベンズイミダゾールおよびイミダゾ−[4,5]−ピリジン |
| DE60334303D1 (de) | 2002-07-03 | 2010-11-04 | Tasuku Honjo | Immunpotenzierende zusammensetzungen |
| WO2006034075A1 (en) * | 2004-09-17 | 2006-03-30 | Osi Pharmaceuticals, Inc. | (hydrazido) (amino) thiophene compounds |
| AU2005295453A1 (en) * | 2004-10-15 | 2006-04-27 | Bayer Healthcare Llc | Preparation and use of biphenyl-4-yl-carbonylamino acid derivatives for the treatment of obesity |
| EP3530736A3 (en) | 2005-05-09 | 2019-11-06 | ONO Pharmaceutical Co., Ltd. | Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics |
| WO2007034282A2 (en) * | 2005-09-19 | 2007-03-29 | Pfizer Products Inc. | Diaryl-imidazole compounds condensed with a heterocycle as c3a receptor antagonists |
| PT2170959E (pt) | 2007-06-18 | 2014-01-07 | Merck Sharp & Dohme | Anticorpos para o receptor humano de morte programada pd-1 |
| EP2297139A1 (en) * | 2008-06-20 | 2011-03-23 | Glaxo Group Limited | Compounds |
| AR072999A1 (es) | 2008-08-11 | 2010-10-06 | Medarex Inc | Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos |
| EA201500417A1 (ru) | 2008-08-25 | 2015-11-30 | Эмплиммьюн, Инк. | Композиции антагонистов pd-1 и способы применения |
| KR101639642B1 (ko) * | 2008-12-05 | 2016-07-14 | 애브비 바하마스 리미티드 | 암 치료에 사용하기 위한 키나제 억제제로서의 티에노[3,2-c]피리딘 유도체 |
| MX356367B (es) | 2008-12-09 | 2018-05-25 | Genentech Inc | Anticuerpos anti-pd-l1 y su uso para mejorar la funcion de celulas t. |
| JP4965623B2 (ja) | 2009-09-30 | 2012-07-04 | インターナショナル・ビジネス・マシーンズ・コーポレーション | 所定のソフトウェアの実行パラメータを入力フィールドへ入力することを支援するための方法、システム、およびプログラム |
| WO2011082098A1 (en) * | 2009-12-30 | 2011-07-07 | The Rockefeller University | Lysine and arginine methyltransferase inhibitors for treating cancer |
| US8907053B2 (en) | 2010-06-25 | 2014-12-09 | Aurigene Discovery Technologies Limited | Immunosuppression modulating compounds |
| WO2013006490A2 (en) | 2011-07-01 | 2013-01-10 | Cellerant Therapeutics, Inc. | Antibodies that specifically bind to tim3 |
| US8895607B2 (en) * | 2011-07-15 | 2014-11-25 | The University Of Montana | Inhibitors of the amino acid transporters ASCT1 and ASCT2 |
| WO2013043569A1 (en) | 2011-09-20 | 2013-03-28 | Vical Incorporated | Synergistic anti-tumor efficacy using alloantigen combination immunotherapy |
| BR112014012819B1 (pt) | 2011-11-28 | 2022-08-16 | Merck Patent Gmbh | Anticorpo anti-pd-l1 ou fragmento de ligação ao antígeno do mesmo e composição |
| US9856320B2 (en) | 2012-05-15 | 2018-01-02 | Bristol-Myers Squibb Company | Cancer immunotherapy by disrupting PD-1/PD-L1 signaling |
| AR091649A1 (es) | 2012-07-02 | 2015-02-18 | Bristol Myers Squibb Co | Optimizacion de anticuerpos que se fijan al gen de activacion de linfocitos 3 (lag-3) y sus usos |
| JP2015525781A (ja) | 2012-07-31 | 2015-09-07 | ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッドThe Brigham and Women’s Hospital, Inc. | 免疫応答の調節 |
| WO2014139388A1 (en) * | 2013-03-14 | 2014-09-18 | Merck Sharp & Dohme Corp. | Novel indole derivatives useful as anti-diabetic agents |
| RS60538B1 (sr) | 2013-03-15 | 2020-08-31 | Glaxosmithkline Ip Dev Ltd | Anti-lag-3 vezujući proteini |
| IL321966A (en) | 2013-09-11 | 2025-09-01 | Medimmune Ltd | Anti-B7-H1 antibodies for tumor treatment |
| TW201605857A (zh) * | 2013-10-03 | 2016-02-16 | 赫孚孟拉羅股份公司 | Cdk8之醫療性抑制劑及其用途 |
| WO2015132672A2 (en) | 2014-03-07 | 2015-09-11 | University Health Network | Methods and compositions for detection of targets involved in cancer metastasis |
| EA201691765A1 (ru) | 2014-03-14 | 2016-12-30 | Новартис Аг | Молекулы антител против lag-3 и их применения |
| WO2016040527A1 (en) * | 2014-09-09 | 2016-03-17 | Vanderbilt University | Metabolism probes for therapy and diagnosis |
| HRP20220237T1 (hr) * | 2016-05-20 | 2022-04-29 | Biohaven Therapeutics Ltd. | Primjena riluzola, prolijekova riluzola ili analoga riluzola sa imunoterapijama za liječenje raka |
| WO2018107173A1 (en) * | 2016-12-09 | 2018-06-14 | Vanderbilt University | Glutamine transport inhibitors and methods for treating cancer |
| TWI886480B (zh) * | 2017-04-06 | 2025-06-11 | 美商富曼西公司 | 殺真菌之噁二唑 |
| CN109369554B (zh) * | 2018-10-18 | 2022-06-17 | 中国药科大学 | 一种含有异羟肟酸的取代杂环类化合物及其制备方法和用途 |
| US20240174658A1 (en) * | 2021-03-01 | 2024-05-30 | Vanderbilt University | Heteroaromatic Inhibitors of Cancer Metabolism |
-
2020
- 2020-06-12 US US17/618,829 patent/US20220304984A1/en active Pending
- 2020-06-12 AU AU2020291464A patent/AU2020291464A1/en not_active Abandoned
- 2020-06-12 WO PCT/US2020/037549 patent/WO2020252353A1/en not_active Ceased
- 2020-06-12 CA CA3141405A patent/CA3141405A1/en active Pending
- 2020-06-12 EP EP20751781.4A patent/EP3983084A1/en not_active Withdrawn
- 2020-06-12 JP JP2021573595A patent/JP2022536419A/ja active Pending
- 2020-06-12 CN CN202080056942.5A patent/CN114222729A/zh active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2018112230A (ru) | Бициклические соединения в качестве ингибиторов atx | |
| JP2023549055A5 (cg-RX-API-DMAC7.html) | ||
| JP2022502424A5 (cg-RX-API-DMAC7.html) | ||
| JP2016504363A5 (cg-RX-API-DMAC7.html) | ||
| JP2011500774A5 (cg-RX-API-DMAC7.html) | ||
| RU2015131148A (ru) | СОЕДИНЕНИЯ, ГЕТЕРОБИЦИКЛО-ЗАМЕЩЕННЫЕ-[1, 2, 4]ТРИАЗОЛО[1, 5c]ХИНАЗОЛИН-5-АМИНА, ОБЛАДАЮЩИЕ СВОЙСТВАМИ А2А АНТАГОНИСТОВ | |
| HRP20240935T1 (hr) | Heterociklični i heteroaril spojevi za liječenje huntingtonove bolesti | |
| JP2021528467A5 (cg-RX-API-DMAC7.html) | ||
| EP3875078A1 (en) | Compounds for the treatment of covid-19 | |
| US20240059703A1 (en) | Heterocyclic spiro compounds and methods of use | |
| JP2015504057A5 (cg-RX-API-DMAC7.html) | ||
| RU2016111675A (ru) | Соединения биарилацетамида и способы их применения | |
| AU2021384833A1 (en) | N-(2,3-dihydro-1,4-benzoxazin-4-yl)-3-isopropyl-7-(2,3,5-trifluorophenyl)benzo-thiophene-2-carboxamide derivatives and similar compounds for the treatment of heartworm infections | |
| JP2021519318A5 (cg-RX-API-DMAC7.html) | ||
| HRP20211483T1 (hr) | Derivati 2-(3-(1h-benzo[d]imidazol-1-il)propil)piperidin-3-ola i povezani spojevi kao inhibitori prs za liječenje npr. raka | |
| BG66066B1 (bg) | Азаиндоли | |
| EA025520B1 (ru) | N-(ГЕТЕРО)АРИЛПИРРОЛИДИНОВЫЕ ПРОИЗВОДНЫЕ ПИРАЗОЛ-4-ИЛ-ПИРРОЛО[2,3-d]ПИРИМИДИНОВ И ПИРРОЛ-3-ИЛ-ПИРРОЛО[2,3-d]ПИРИМИДИНОВ В КАЧЕСТВЕ ИНГИБИТОРОВ ЯНУС-КИНАЗЫ | |
| RU2013136778A (ru) | Ингибиторы гистондезацетилазы, композиции и способы их применения | |
| WO2022093856A1 (en) | Heterocyclic spiro compounds and methods of use | |
| JP2021512954A5 (cg-RX-API-DMAC7.html) | ||
| JP2021501806A5 (cg-RX-API-DMAC7.html) | ||
| JP2022502440A5 (cg-RX-API-DMAC7.html) | ||
| CN115768762A (zh) | 用于治疗亨廷顿氏病的化合物 | |
| US20240109900A1 (en) | Azabicyclic shp2 inhibitors | |
| JP2020511412A5 (cg-RX-API-DMAC7.html) |